Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

277 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Acute myeloid leukemia drug tolerant persister cells survive chemotherapy by transiently increasing plasma membrane rigidity, that also increases their sensitivity to immune cell killing.
Morgenstern Y, Lee J, Na Y, Lieng BY, Ly NS, Gwynne WD, Hurren R, Ma L, Ling D, Gronda M, Arruda A, Frisch A, Zuckerman T, Ofran Y, Minden MD, Zhang L, O'Brien C, Quaile AT, Montenegro-Burke JR, Schimmer AD. Morgenstern Y, et al. Among authors: schimmer ad. Haematologica. 2024 Nov 21. doi: 10.3324/haematol.2024.286018. Online ahead of print. Haematologica. 2024. PMID: 39568440 Free article.
The thymidine dideoxynucleoside analog, alovudine, inhibits the mitochondrial DNA polymerase γ, impairs oxidative phosphorylation and promotes monocytic differentiation in acute myeloid leukemia.
Yehudai D, Liyanage SU, Hurren R, Rizoska B, Albertella M, Gronda M, Jeyaraju DV, Wang X, Barghout SH, MacLean N, Siriwardena TP, Jitkova Y, Targett-Adams P, Schimmer AD. Yehudai D, et al. Among authors: schimmer ad. Haematologica. 2019 May;104(5):963-972. doi: 10.3324/haematol.2018.195172. Epub 2018 Dec 20. Haematologica. 2019. PMID: 30573504 Free PMC article.
Novel L-nucleoside analogue, 5-fluorotroxacitabine, displays potent efficacy against acute myeloid leukemia.
Bankar A, Siriwardena TP, Rizoska B, Rydergård C, Kylefjord H, Rraklli V, Eneroth A, Pinho P, Norin S, Bylund J, Moses S, Bethell R, Kavanagh S, Maclean N, Gronda M, Wang X, Hurren R, Minden MD, Targett-Adams P, Schimmer AD, Albertella M. Bankar A, et al. Among authors: schimmer ad. Haematologica. 2021 Feb 1;106(2):574-579. doi: 10.3324/haematol.2019.226795. Haematologica. 2021. PMID: 31857370 Free PMC article. No abstract available.
Venetoclax enhances T cell-mediated antileukemic activity by increasing ROS production.
Lee JB, Khan DH, Hurren R, Xu M, Na Y, Kang H, Mirali S, Wang X, Gronda M, Jitkova Y, MacLean N, Arruda A, Alaniz Z, Konopleva MY, Andreeff M, Minden MD, Zhang L, Schimmer AD. Lee JB, et al. Among authors: schimmer ad. Blood. 2021 Jul 22;138(3):234-245. doi: 10.1182/blood.2020009081. Blood. 2021. PMID: 34292323 Free PMC article.
Exclusion of persistent mutations in splicing factor genes and isocitrate dehydrogenase 2 improves the prognostic power of molecular measurable residual disease assessment in acute myeloid leukemia.
Murphy T, Zou J, Arruda A, Wang TT, Zhao Z, Zheng Y, Gupta V, Maze D, McNamara C, Minden MD, Schimmer A, Sibai H, Yee K, Capo-Chichi JM, Stockley T, Schuh A, Bratman SV, Chan SM. Murphy T, et al. Haematologica. 2024 Feb 1;109(2):671-675. doi: 10.3324/haematol.2023.283510. Haematologica. 2024. PMID: 37345484 Free PMC article. No abstract available.
277 results